Maxim Group assumed coverage on shares of Nasus Pharma (NYSEAMERICAN:NSRX – Free Report) in a report released on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $7.00 target price on the stock.
Nasus Pharma Stock Performance
NYSEAMERICAN NSRX opened at $3.07 on Friday. Nasus Pharma has a twelve month low of $1.98 and a twelve month high of $9.50. The stock’s 50 day moving average is $3.58 and its 200 day moving average is $3.65.
Nasus Pharma (NYSEAMERICAN:NSRX – Get Free Report) last posted its earnings results on Monday, August 17th. The company reported ($0.27) EPS for the quarter. As a group, equities analysts predict that Nasus Pharma will post -0.84 EPS for the current year.
About Nasus Pharma
Nasus Pharma Ltd. is a specialty pharmaceutical company focused on developing intranasal powder-based medicines. Its proprietary platform is designed to deliver drug therapies through the nose, with the potential to support rapid administration without the need for injections or other conventional delivery methods.
The company’s development efforts are directed toward acute and emergency-care applications, including treatments for conditions in which rapid drug delivery may be important.
Further Reading
- Five stocks we like better than Nasus Pharma
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Nasus Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nasus Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
